Amjad Waseem, Kamal Faisal, Malik Adnan, Singh Ritu, Mahmood Sultan
Department of Internal Medicine, Albany Medical Center, Albany, NY, USA.
Department of Gastroenterology, University of Tennessee, Memphis, TN, USA.
Prz Gastroenterol. 2022;17(2):146-151. doi: 10.5114/pg.2021.107799. Epub 2021 Jul 14.
Some observational studies have demonstrated the benefit of famotidine in COVID-19-infected individuals. The preference of using an H receptor antagonist (HRA) over proton pump inhibitors (PPI) during the COVID-19 pandemic has been questioned by clinicians.
To compare the outcomes of hospitalized patients who were taking HRA vs. PPI.
We conducted a retrospective review of patients admitted for COVID-19 infection from 1 March until 31 July 2020. We included 396 patients admitted during the study period. Of the total, 39 (9.8%) received HRA and 86 (21.7%) were taking PPI as home medications; 6 patients were taking both HRA and PPI.
The baseline characteristics and comorbid conditions were similar in both groups. The mean age was 57.79 ±17.36 years, 43.2% were female, and 48.7% were Caucasian. The common comorbid conditions included HTN (56.8%), obesity (44.4%), diabetes mellitus (38.6%), and coronary artery disease (30.1%). Smoking was more prevalent in the PPI group (42.5% vs. 18.2%, = 0.03). Gastrointestinal symptoms were seen on initial presentation in 31.1%, and 43.9% had elevated liver enzymes. The HRA group had similar mortality (HR = 0.84, 95% CI: 0.35-2.05) to the non-HB group. It remained non-significant as compared to PPI (HR = 0.34-3.19, 95% CI: 0.34-3.19). The secondary outcomes including readmission, ICU admission, and severe COVID infections (including ARDS and thromboembolism) were similar in these groups.
The H receptor antagonist used as a home medication did not show benefit over the PPI in patients admitted for COVID-19 infections.
一些观察性研究已证明法莫替丁对新冠病毒感染个体有益。在新冠疫情期间，相较于质子泵抑制剂（PPI），使用H受体拮抗剂（HRA）的偏好受到了临床医生的质疑。
比较服用HRA与PPI的住院患者的治疗结果。
我们对2020年3月1日至7月31日因新冠病毒感染入院的患者进行了回顾性研究。我们纳入了研究期间入院的396例患者。其中，39例（9.8%）接受HRA治疗，86例（21.7%）在家服用PPI；6例同时服用HRA和PPI。
两组的基线特征和合并症相似。平均年龄为57.79±17.36岁，43.2%为女性，48.7%为白种人。常见合并症包括高血压（56.8%）、肥胖（44.4%）、糖尿病（38.6%）和冠状动脉疾病（30.1%）。吸烟在PPI组更为普遍（42.5%对18.2%，P = 0.03）。初次就诊时31.1%有胃肠道症状，43.9%肝酶升高。HRA组与非HRA组的死亡率相似（HR = 0.84，95%CI：0.35 - 2.05）。与PPI组相比仍无显著差异（HR = 0.34 - 3.19，95%CI：0.34 - 3.19）。这些组的二次结局包括再次入院、入住重症监护病房和严重新冠感染（包括急性呼吸窘迫综合征和血栓栓塞）相似。
对于因新冠病毒感染入院的患者，在家服用的H受体拮抗剂相较于PPI未显示出优势。
